Process and monoclonal antibody for the specific determination of pancreatic .alpha.-amylase in the presence of salivary .alpha.-amylase
US5071744A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 9, 1990 |
| Grant date | Dec 10, 1991 |
| Priority date | — |
| Expiry date | Oct 9, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/975
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Pancreatic .alpha.-amylase is determined in body fluid in the presence of salivary .alpha.-amylase by combining the body fluid with a monoclonal antibody that inhibits salivary .alpha.-amylase by 95% or more and inhibits pancreatic .alpha.-amylase by 50% or less, and then detecting pancreatic .alpha.-amylase with a system for the detection of .alpha.-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing .beta.-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary .alpha.-amylase, aluminum hydroxide and Bortadella pertussis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.